For research use only. Not for therapeutic Use.
CP 471474 is a matrix metalloprotease inhibitor with sub-nanomolar affinity for MMP-2 and 13 among a broad range of MMPs (IC50: 1170, 0.7, 16, 13, 0.9 for MMP-1, MMP-2, MMP-3, MMP-9, and MMP-13 respectively). It attenuates early left ventricular dilation after experimental myocardial infarction in mice. Similarly, CP-471474 attenuated both the early inflammatory response and the emphysematous lesions induced by chronic exposure to cigarette smoke in guinea pigs.
Catalog Number | R053498 |
CAS Number | 210755-45-6 |
Molecular Formula | C16H17FN2O5S |
Purity | ≥95% |
IUPAC Name | 2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-N-hydroxy-2-methylpropanamide |
InChI | InChI=1S/C16H17FN2O5S/c1-16(2,15(20)18-21)19-25(22,23)14-9-7-13(8-10-14)24-12-5-3-11(17)4-6-12/h3-10,19,21H,1-2H3,(H,18,20) |
SMILES | CC(C)(C(=O)NO)NS(=O)(=O)C1=CC=C(C=C1)OC2=CC=C(C=C2)F |
Reference | LA Reiter et al. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. Bioorg. Med. Chem. Lett. 2004, 14, 3389-3395.
LE Rohde et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 99, 3063-3070.
M Selman et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 2003, 123, 1633-1641. |